Prevalence of disease-modifying drug treatment gaps in patients with multiple sclerosis

被引：0
|
作者：
Joyeux, A.
Kozma, C.
Meletiche, D.
Dickson, M.
Bennett, R.
机构：
[1] Merck Serono, Geneva, Switzerland
[2] Univ S Carolina, Columbia, SC 29208 USA
[3] EMD Serono Inc, Rockland, ME USA
来源：
JOURNAL OF NEUROLOGY | 2009年 / 256卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S163 / S163
页数：1
相关论文
共 50 条
  • [21] Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis
    Vartanian, TK
    Zamvil, SS
    Fox, E
    Sorensen, PS
    NEUROLOGY, 2004, 63 (11) : S42 - S49
  • [22] Association of Timing of Disease-Modifying Drug Treatment Initiation on Multiple Sclerosis Relapse Rates in Newly Diagnosed Patients
    Phillips, Amy
    Fang, Juanzhi
    Corvino, Frank
    Oliveri, David
    NEUROLOGY, 2016, 86
  • [23] Factors associated with early initiation of disease-modifying drug treatment in newly-diagnosed patients with multiple sclerosis
    Edwards, Natalie C.
    Munsell, Michael
    Menzim, Joseph
    Phillips, Amy L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (08) : 1389 - 1395
  • [24] Commentary Adverse Drug Reactions of Multiple Sclerosis Disease-modifying Drugs
    Salehbayat, Maryam
    Abolfazli, Roya
    Mohebbi, Niayesh
    Savar, Seyed Mehrdad
    Shalviri, Gloria
    Gholami, Kheirollah
    BASIC AND CLINICAL NEUROSCIENCE, 2023, 14 (06) : 879 - 884
  • [25] Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
    Morillo Verdugo, Ramon
    Ramirez Herraiz, Esther
    Fernandez-Del Olmo, Raquel
    Roig Bonet, Montserrat
    Valdivia Garcia, Maria
    PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 261 - 272
  • [26] Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies
    Grebenciucova, Elena
    Pruitt, Amy
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2017, 17 (11)
  • [27] Infections in patients with multiple sclerosis: Implications for disease-modifying therapy
    Celius, E. G.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 : 34 - 36
  • [28] FIRST USE OF DISEASE-MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS
    Meletiche, D. M.
    Kozma, C.
    Dickson, M.
    VALUE IN HEALTH, 2009, 12 (03) : A193 - A193
  • [29] Prescribing disease-modifying treatments for older patients with multiple sclerosis
    Lopez Ruiz, Rocio
    Eichau Madueno, Sara
    Cortes Zujar, Beatriz
    Canaveral, Marta
    Arzalluz, Joaquin
    Ben Yelun Insenser, Miriam
    Dotor, Julio
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1086 - 1086
  • [30] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Simona Lattanzi
    Maura Danni
    Ruja Taffi
    Raffaella Cerqua
    Giulia Carlini
    Alessandra Pulcini
    Leandro Provinciali
    Mauro Silvestrini
    Journal of Neurology, 2017, 264 : 2325 - 2329
12345